On January 6, 2016 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) reported that Chugai and Novartis Pharma K.K. have agreed to terminate the agreement regarding co-marketing of aromatase inhibitor "Femara tablets 2.5 mg" (generic name: letrozole, hereafter Femara), a treatment for breast cancer after menopause in Japan, as of January 31, 2016 (Press release, Chugai, JAN 6, 2016, View Source [SID:1234508670]). Schedule your 30 min Free 1stOncology Demo! Novartis Pharma will be solely responsible for the distribution and commercialization of Femara in Japan from February 1, 2016.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Chugai and Novartis Pharma will cooperate to accomplish a smooth transition. During the transition period, both companies will maintain the same level of product supply and adequate commercial activities to satisfy any medical needs.